Extended protection against phlebovirus infection conferred by recombinant adenovirus expressing consensus interferon (DEF201)

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 8, 2012, Pages 4168-4174

  Gowen, Brian B ^a   Ennis, Jane ^b   Sefing, Eric J ^a   Wong, Min Hui ^a   Jung, Kie Hoon ^a   Turner, Jeffrey D ^b  

^a UTAH STATE UNIVERSITY   (United States)

^b Defyrus Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; DEF 201; RECOMBINANT ALPHA INTERFERON; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; FEMALE; HAMSTER; HOST CELL; IMMUNE RESPONSE; IN VIVO STUDY; INNATE IMMUNITY; NONHUMAN; PHLEBOVIRUS INFECTION; PRIORITY JOURNAL; VIRUS REPLICATION;

ADENOVIRIDAE; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIVIRAL AGENTS; BUNYAVIRIDAE INFECTIONS; CRICETINAE; FEMALE; GENETIC VECTORS; INTERFERON-ALPHA; LIVER; MESOCRICETUS; PHLEBOVIRUS; RECOMBINANT PROTEINS;

EID: 84864381131     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00376-12     Document Type: Article

References (25)

1. Alkhatib G, Richardson C, Shen SH. 1990. Intracellular processing, glycosylation, and cell-surface expression of the measles virus fusion protein (F) encoded by a recombinant adenovirus. Virology 175:262-270. (Pubitemid 20093082)
2. Anyamba A, et al. 2010. Prediction, assessment of the Rift Valley fever activity in East and Southern Africa 2006-2008 and possible vector control strategies. Am. J. Trop. Med. Hyg. 83:43-51.
3. Bird BH, Ksiazek TG, Nichol ST, Maclachlan NJ. 2009. Rift Valley fever virus. J. Am. Vet. Med. Assoc. 234:883-893.
4. Borden EC, Williams BR. 2011. Interferon-stimulated genes and their protein products: what and how? J. Interferon Cytokine Res. 31:1-4.
5. Gerdes GH. 2002. Rift Valley fever. Vet. Clin. North Am. Food Anim. Pract. 18:549-555.
6. Gowen BB, et al. 2005. Interferon alfacon-1 protects hamsters from lethal Pichinde virus infection. Antimicrob. Agents Chemother. 49:2378-2386. (Pubitemid 40734470)
7. Gowen BB, et al. 2011. Use of recombinant adenovirus vectored consensus IFN-α to avert severe arenavirus infection. PLoS One 6:e26072. doi:10.1371/journal.pone.0026072.
8. Gowen BB, et al. 2009. Prophylaxis with cationic liposome-DNA complexes protects hamsters from phleboviral disease: importance of liposomal delivery and CpG motifs. Antiviral Res. 81:37-46.
9. Gowen BB, Holbrook MR. 2008. Animal models of highly pathogenic RNA viral infections: hemorrhagic fever viruses. Antiviral Res. 78:79-90. (Pubitemid 351381175)
10. Gowen BB, Wong MH, Jung KH, Blatt LM, Sidwell RW. 2008. Prophylactic and therapeutic intervention of Punta Toro virus (Phlebovirus, Bunyaviridae) infection in hamsters with interferon alfacon-1. Antiviral Res. 77:215-224.
11. Gowen BB, et al. 2007. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob. Agents Chemother. 51:3168-3176. (Pubitemid 350067524)
12. Julander JG, Ennis J, Turner J, Morrey JD. 2011. Treatment of yellow fever virus with an adenovirus-vectored interferon, DEF201, in a hamster model. Antimicrob. Agents Chemother. 55:2067-2073.
13. Kumaki Y, et al. 2011. Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model. Antiviral Res. 89:75-82.
14. Marshall GS, Fenger DP, Stout GG, Knights ME, Hunt LA. 1996. Processing of human cytomegalovirus glycoprotein B in recombinant adenovirus-infected cells. J. Gen. Virol. 77:1549-1557. (Pubitemid 26248670)
15. Morrill JC, Jennings GB, Cosgriff TM, Gibbs PH, Peters CJ. 1989. Prevention of Rift Valley fever in rhesus monkeys with interferon-alpha. Rev. Infect. Dis. 11(Suppl 4):S815-S825.
16. Morrill JC, et al. 1990. Pathogenesis of Rift Valley fever in rhesus monkeys: role of interferon response. Arch. Virol. 110:195-212. (Pubitemid 20132161)
17. NIAID. 2002. Counter-bioterrorism research agenda of the National Institute of Allergy and Infectious Diseases (NIAID) for CDC category A agents. NIAID, Bethesda, MD.
18. Peters CJ, Reynolds JA, Slone TW, Jones DE, Stephen EL. 1986. Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator. Antiviral Res. 6:285-297. (Pubitemid 16043762)
19. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. (Lond.) 27:493-497.
20. Samuel CE. 2001. Antiviral actions of interferons. Clin. Microbiol. Rev. 14:778-809. (Pubitemid 32979631)
21. Sen GC. 2001. Viruses and interferons. Annu. Rev. Microbiol. 55:255-281. (Pubitemid 32978106)
22. Sidwell RW, et al. 1994. Antiviral and immunomodulating inhibitors of experimentally induced Punta Toro virus infections. Antiviral Res. 25:105-122. (Pubitemid 24308528)
23. Smee DF, Wong MH, Russell A, Ennis J, Turner JD. 2011. Therapy and long-term prophylaxis of vaccinia virus respiratory infections in mice with an adenovirus-vectored interferon alpha (mDEF201). PLoS One 6:e26330. doi:10.1371/journal.pone.0026330.
24. Weaver SC, Reisen WK. 2010. Present and future arboviral threats. Antiviral Res. 85:328-345.
25. Wong G, et al. 2011. Evaluation of different strategies for post-exposure treatment of Ebola virus infection in rodents. J. Bioterr. Biodef. S1:007. doi:10.4172/2157-2526.S1-007.